Cargando…

CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease

The development of cyclin-dependent kinase (CDK) 4/6 inhibitors has been more prominent in hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancers, with a significant improvement in progression-free survival (PFS) in first and later lines of metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matutino, Adriana, Amaro, Carla, Verma, Sunil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299331/ https://www.ncbi.nlm.nih.gov/pubmed/30619511 http://dx.doi.org/10.1177/1758835918818346

Ejemplares similares

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
por: Ma, Jun, et al.
Publicado: (2023)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2021)

The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
por: Grinshpun, Albert, et al.
Publicado: (2023)

ESMO20 YO for YO: highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancer
por: Matikas, A., et al.
Publicado: (2020)

CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis
por: Agostinetto, E., et al.
Publicado: (2021)

CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?
por: Yam, Clinton, et al.
Publicado: (2018)

Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
por: Di Cosimo, Serena, et al.
Publicado: (2020)

The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature
por: Botticelli, Andrea, et al.
Publicado: (2022)

Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
por: Jeong, Hyehyun, et al.
Publicado: (2022)

CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives
por: Roberto, Michela, et al.
Publicado: (2021)

Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
por: Lin, Mingxi, et al.
Publicado: (2020)

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)
por: Futamura, Manabu, et al.
Publicado: (2023)

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
por: Lu, Janice
Publicado: (2015)

Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
por: Davis, Andrew A., et al.
Publicado: (2023)

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
por: Zattarin, Emma, et al.
Publicado: (2023)

CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
por: de Melo Gagliato, Debora, et al.
Publicado: (2020)

Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer
por: Byers, Kristina F.
Publicado: (2021)

Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer
por: Lee, Jin Sun, et al.
Publicado: (2022)

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis
por: Ji, Danyang, et al.
Publicado: (2023)

Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)
por: Decker, Thomas, et al.
Publicado: (2023)

Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression
por: Horani, Malek, et al.
Publicado: (2023)

A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer: a review of CDK inhibitors
por: Fernandes, Mariane Teodoro, et al.
Publicado: (2018)

Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer
por: Franks, Jeffrey, et al.
Publicado: (2022)

CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
por: Nabieva, Naiba, et al.
Publicado: (2023)

Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer
por: Khorrami, Mohammadhadi, et al.
Publicado: (2023)

Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2−) breast cancer: a systematic review
por: Zhu, Linhui, et al.
Publicado: (2022)

Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors
por: Li, Chao, et al.
Publicado: (2021)

Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel
por: Trapé, Adriana Priscila, et al.
Publicado: (2016)

Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors
por: O’Sullivan, Ciara C
Publicado: (2015)

Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
por: Watt, April C., et al.
Publicado: (2022)

CDK4/6 inhibitors for hormone receptor-positive/human epidermal growth factor receptor 2 negative advanced breast cancer: A rapid health technology assessment
por: Gu, Hangye, et al.
Publicado: (2023)

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
por: Rossi, Lorenzo, et al.
Publicado: (2018)

EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer
por: Almstedt, K., et al.
Publicado: (2020)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
por: Scheidemann, Erin R., et al.
Publicado: (2021)

CDK4/6 inhibitors in advanced breast cancer, what is beyond?
por: Mohammed, Amrallah A., et al.
Publicado: (2019)

MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer
por: Portman, Neil, et al.
Publicado: (2021)

Role of CDK4/6 inhibitors in patients with hormone receptor (HR)-positive, human epidermal receptor-2 negative (HER-2) metastatic breast cancer study protocol for a systematic review, network meta-analysis and cost-effectiveness analysis
por: Hu, Qiancheng, et al.
Publicado: (2022)

The emerging role of CDK4/6i in HER2-positive breast cancer
por: O’Sullivan, Ciara C., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_19tn42erj09ac31lt8msovnqj2